Gateways to clinical trials.

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Methods and Findings in Experimental and Clinical Pharmacology

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  PMID 15148527
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck.

  2004cited by this paper
• Phase III study of N,N-diethyl-2-[4-(phenylmethyl) phenoxy]ethanamine (BMS-217380-01) combined with doxorubicin versus doxorubicin alone in metastatic/recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group Study MA.19.

  2004cited by this paper
• Pilot trial of 1-octanol in essential tremor

  2004cited by this paper
• Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B.

  2004cited by this paper
• Six-Week Randomized Controlled Trial To Compare the Tolerabilities, Pharmacokinetics, and Antiviral Activities of GW433908 and Amprenavir in Human Immunodeficiency Virus Type 1-Infected Patients

  2004cited by this paper
• Oral modified insulin (HIM2) in patients with type 1 diabetes mellitus: results from a phase I/II clinical trial.

  2004cited by this paper
• Phase I clinical and pharmacokinetic study of BBR 3576, a novel aza-anthrapyrazole, administered i.v. every 4 weeks in patients with advanced solid tumors: a phase I study group trial of the Central European Society of Anticancer-Drug Research (CESAR)

  2004cited by this paper
• Phase II trial of PS-341 in patients with renal cell cancer: a University of Chicago phase II consortium study.

  2004cited by this paper
• The safety and tolerability of a mixed lineage kinase inhibitor (CEP-1347) in PD

  2004cited by this paper
• Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus.

  2004cited by this paper
• Intensive therapy with inhaled insulin via the AERx insulin diabetes management system: a 12-week proof-of-concept trial in patients with type 2 diabetes.

  2004cited by this paper
• A phase I trial of intranasal Moli1901 for cystic fibrosis.

  2004cited by this paper
• Phase II trial of gefitinib in recurrent glioblastoma.

  2004cited by this paper
• Pregabalin Add‐on Treatment: A Randomized, Double‐blind, Placebo‐controlled, Dose–Response Study in Adults with Partial Seizures

  2004cited by this paper
• Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria.

  2004cited by this paper
• Does melatonin improve sleep in older people? A randomised crossover trial.

  2003cited by this paper
• Ragaglitazar: the pharmacokinetics, pharmacodynamics, and tolerability of a novel dual PPAR alpha and gamma agonist in healthy subjects and patients with type 2 diabetes.

  2003cited by this paper
• A 12-month, open-label, multicenter extension trial of orally administered sodium oxybate for the treatment of narcolepsy.

  2003cited by this paper
• Effect of coadministration of ezetimibe and simvastatin on high-sensitivity C-reactive protein.

  2003cited by this paper
• Recombinant glucagon-like peptide-1 (7-36 amide) lowers fasting serum glucose in a broad spectrum of patients with type 2 diabetes.

  2003cited by this paper
• A multicenter retrospective cohort study of practice patterns and clinical outcomes of the use of darbepoetin alfa and epoetin alfa for chemotherapy-induced anemia.

  2003cited by this paper
• A phase II study to determine the efficacy and tolerability of intravenous ZD9331 in heavily pretreated patients with ovarian cancer.

  2003cited by this paper
• A randomized controlled trial (volunteer study) of sitafloxacin, enoxacin, levofloxacin and sparfloxacin phototoxicity

  2003cited by this paper
• A phase II study of bryostatin-1 and paclitaxel in patients with advanced non-small cell lung cancer.

  2003cited by this paper
• Melatonin in Children and Adolescents with Insomnia: A Retrospective Study

  2003cited by this paper
• Phase I and pharmacokinetic study of Yondelis (Ecteinascidin-743; ET-743) administered as an infusion over 1 h or 3 h every 21 days in patients with solid tumours.

  2003cited by this paper
• Melatonin improves health status and sleep in children with idiopathic chronic sleep-onset insomnia: a randomized placebo-controlled trial.

  2003cited by this paper
• Nestorone: clinical applications for contraception and HRT.

  2003cited by this paper
• Phase I and pharmacokinetic study of E7070, a chloroindolyl-sulfonamide anticancer agent, administered on a weekly schedule to patients with solid tumors.

  2003cited by this paper
• Phase I and pharmacodynamic study of Triapine, a novel ribonucleotide reductase inhibitor, in patients with advanced leukemia.

  2003cited by this paper
• Ertapenem Therapy for Community‐Acquired Pneumonia in the Elderly

  2003cited by this paper
• Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis).

  2003cited by this paper
• Glufosfamide administered using a 1-hour infusion given as first-line treatment for advanced pancreatic cancer. A phase II trial of the EORTC-new drug development group.

  2003cited by this paper
• European Organization for Research and Treatment of Cancer (EORTC) open label phase II study on glufosfamide administered as a 60-minute infusion every 3 weeks in recurrent glioblastoma multiforme.

  2003cited by this paper
• Dehydroepiandrosterone supplementation improves endothelial function and insulin sensitivity in men.

  2003cited by this paper
• Phase I and pharmacokinetic trial of the novel taxane BMS-184476 administered as a 1-hour intravenous infusion in combination with cisplatin every 21 days.

  2003cited by this paper
• Pramlintide reduces postprandial glucose excursions when added to regular insulin or insulin lispro in subjects with type 1 diabetes: a dose-timing study.

  2003cited by this paper
• Effects of D-003 on the Lipid Profile of Patients with Type II Hypercholesterolaemia

  2003cited by this paper
• The calcimimetic cinacalcet normalizes serum calcium in subjects with primary hyperparathyroidism.

  2003cited by this paper
• Phase I clinical trial and pharmacokinetic study of the spicamycin analog KRN5500 administered as a 1-hour intravenous infusion for five consecutive days to patients with refractory solid tumors.

  2003cited by this paper
• Phase I therapy study with (186)Re-labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with head and neck squamous cell carcinoma.

  2003cited by this paper
• A phase II study of rebeccamycin analog (NSC-655649) in metastatic renal cell cancer

  2003cited by this paper
• Tolerability of retreatment with omalizumab, a recombinant humanized monoclonal anti-IgE antibody, during a second ragweed pollen season in patients with seasonal allergic rhinitis.

  2003cited by this paper
• A randomized phase II evaluation of bryostatin-1 (NSC #339555) in persistent or recurrent squamous cell carcinoma of the cervix: A Gynecologic Oncology Group Study

  2003cited by this paper
• Phase I clinical trial of the bispecific antibody MDX-H210 (anti-FcγRI × anti-HER-2/neu) in combination with Filgrastim (G-CSF) for treatment of advanced breast cancer

  2003cited by this paper
• Phase I and pharmacokinetic study of BMS-188797, a new taxane analog, administered on a weekly schedule in patients with advanced malignancies.

  2003cited by this paper
• Avasimibe, an ACAT inhibitor, enhances the lipid lowering effect of atorvastatin in subjects with homozygous familial hypercholesterolemia.

  2003cited by this paper
• A phase II trial of pemetrexed in patients with metastatic renal cancer

  2003cited by this paper

• Co-targeting of specific epigenetic regulators in combination with CDC7 potently inhibit melanoma growth

  2022cites this paper
• Hypoxia: Importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapy

  2006cites this paper
• CD44v6, a target for novel antibody treatment approaches, is frequently expressed in multiple myeloma and associated with deletion of chromosome arm 13q.

  2005cites this paper